Skip to content

Study · Non-randomized trial · n = 21 · 2000

12 results

Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo.

Raderer M, Hejna MH, Muller C, Kornek GV, Kurtaran A, Virgolini I, Fiebieger W, Hamilton G, Scheithauer W

International journal of oncology1 Jun 2000Cited by 47 (Europe PMC)

PMID10811995 (opens in a new tab)DOI10.3892/ijo.16.6.1197 (opens in a new tab)PepBankPUB-10811995
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In advanced HCC, one lanreotide-treated patient (5%) had a partial response.

    In plain wordsIn advanced liver cancer, one lanreotide-treated patient (5%) had a partial response.

    Peptide
    Lanreotide
    Outcome
    Not applicablePartial response
    Study

    n = 21

    Outcome group
    Tumor growth · Cancer
    Studied dose
    30 mg every 14 days · deep intramuscular · until disease progressionAs given in this study (human).

    Measurements

    Patients with partial response
    5%
    advanced HCC, 1 patient

    Source sentences

    Summary
    One patient (5%) showed a partial response to treatment, 8 patients had stable disease (38%), while the remaining patients progressed during treatment.
  2. 02HumanNon-randomized trialEfficacy outcome

    In advanced HCC, 8 lanreotide-treated patients (38%) had stable disease.

    In plain wordsIn advanced liver cancer, eight lanreotide-treated patients (38%) had stable disease.

    Peptide
    Lanreotide
    Outcome
    Not applicableStable disease
    Study

    n = 21

    Outcome group
    Tumor growth · Cancer
    Studied dose
    30 mg every 14 days · deep intramuscular · until disease progressionAs given in this study (human).

    Measurements

    Patients with stable disease
    38%
    advanced HCC, 8 patients

    Source sentences

    Summary
    One patient (5%) showed a partial response to treatment, 8 patients had stable disease (38%), while the remaining patients progressed during treatment.
  3. 03HumanNon-randomized trialEfficacy outcome

    In advanced HCC, patients other than those with partial response or stable disease progressed during lanreotide treatment.

    In plain wordsIn advanced liver cancer, the remaining patients had disease progression during lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    Not applicableDisease progression
    Study

    n = 21

    Outcome group
    Tumor growth · Cancer
    Studied dose
    30 mg every 14 days · deep intramuscular · until disease progressionAs given in this study (human).

    Source sentences

    Summary
    One patient (5%) showed a partial response to treatment, 8 patients had stable disease (38%), while the remaining patients progressed during treatment.
  4. 04HumanNon-randomized trialEfficacy outcome

    In advanced HCC treated with lanreotide, median survival was 4.2 months (range 1.2-13+).

    In plain wordsIn advanced liver cancer treated with lanreotide, median survival was 4.2 months.

    Peptide
    Lanreotide
    Outcome
    Not applicableSurvival
    Study

    n = 21

    Outcome group
    Mortality · Cancer
    Studied dose
    30 mg every 14 days · deep intramuscular · until disease progressionAs given in this study (human).

    Measurements

    Median survival
    4.2 months
    advanced HCC
    Survival range
    1.2 to 13 months
    advanced HCC; upper bound reported as 13+

    Source sentences

    Summary
    The median survival was 4.2 months (range 1.2-13+), and the median time to progression was 2.5 months (range, 1.5-7+).
  5. 05HumanNon-randomized trialEfficacy outcome

    In advanced HCC treated with lanreotide, median time to progression was 2.5 months (range 1.5-7+).

    In plain wordsIn advanced liver cancer treated with lanreotide, median time to progression was 2.5 months.

    Peptide
    Lanreotide
    Outcome
    Not applicableTime to progression
    Study

    n = 21

    Outcome group
    Tumor growth · Cancer
    Studied dose
    30 mg every 14 days · deep intramuscular · until disease progressionAs given in this study (human).

    Measurements

    Median time to progression
    2.5 months
    advanced HCC
    Time to progression range
    1.5 to 7 months
    advanced HCC; upper bound reported as 7+

    Source sentences

    Summary
    The median survival was 4.2 months (range 1.2-13+), and the median time to progression was 2.5 months (range, 1.5-7+).
  6. 06HumanNon-randomized trialEfficacy outcome

    In advanced HCC, 4 lanreotide-treated patients (19%) had increased WHO performance status lasting 2.5 to 6 months.

    In plain wordsIn advanced liver cancer, four lanreotide-treated patients had increased WHO performance status for 2.5 to 6 months.

    Peptide
    Lanreotide
    Outcome
    IncreaseWHO performance status
    Study

    n = 21

    Outcome group
    Exercise and physical function · Cancer
    Studied dose
    30 mg every 14 days · deep intramuscular · until disease progressionAs given in this study (human).

    Measurements

    Patients with increased WHO performance status
    19%
    advanced HCC, 4 patients
    Duration of WHO performance status increase
    2.5 to 6 months
    advanced HCC

    Source sentences

    Summary
    However, 4 patients (19%) had an increase in WHO performance status lasting between 2.5 and 6 months, 5 patients (24%) had an increase in body weight, while pain markedly improved in 1 additional patient (5%).
  7. 07HumanNon-randomized trialEfficacy outcome

    In advanced HCC, 5 lanreotide-treated patients (24%) gained body weight.

    In plain wordsIn advanced liver cancer, five lanreotide-treated patients (24%) gained weight.

    Peptide
    Lanreotide
    Outcome
    IncreaseBody weight
    Study

    n = 21

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    30 mg every 14 days · deep intramuscular · until disease progressionAs given in this study (human).

    Measurements

    Patients with increased body weight
    24%
    advanced HCC, 5 patients

    Source sentences

    Summary
    However, 4 patients (19%) had an increase in WHO performance status lasting between 2.5 and 6 months, 5 patients (24%) had an increase in body weight, while pain markedly improved in 1 additional patient (5%).
  8. 08HumanNon-randomized trialEfficacy outcome

    In advanced HCC, pain markedly improved in one additional lanreotide-treated patient (5%).

    In plain wordsIn advanced liver cancer, pain markedly improved in one additional lanreotide-treated patient (5%).

    Peptide
    Lanreotide
    Outcome
    DecreasePain
    Study

    n = 21

    Outcome group
    Pain · Cancer
    Studied dose
    30 mg every 14 days · deep intramuscular · until disease progressionAs given in this study (human).

    Measurements

    Additional patients with markedly improved pain
    5%
    advanced HCC, 1 patient

    Source sentences

    Summary
    However, 4 patients (19%) had an increase in WHO performance status lasting between 2.5 and 6 months, 5 patients (24%) had an increase in body weight, while pain markedly improved in 1 additional patient (5%).
  9. 09HumanNon-randomized trialEfficacy outcome

    In advanced HCC, 5 lanreotide-treated patients (24%) had serum AFP decreases of at least 30%.

    In plain wordsIn advanced liver cancer, five lanreotide-treated patients (24%) had blood AFP decreases of at least 30%.

    Peptide
    Lanreotide
    Outcome
    DecreaseSerum AFP
    Study

    n = 21

    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    30 mg every 14 days · deep intramuscular · until disease progressionAs given in this study (human).

    Measurements

    Patients with serum AFP decrease
    24%
    advanced HCC, 5 patients
    Serum AFP decrease threshold
    ≥ 30%
    advanced HCC, decrease of at least 30%

    Source sentences

    Summary
    In total, 5 patients (24%) had a decrease in serum-AFP levels by at least 30%.
  10. 10LabIn vitro (cells)Efficacy outcome

    In Hep G2 cells, lanreotide decreased the S-phase fraction versus controls (p<0.03).

    In plain wordsIn cells, lanreotide reduced the fraction in the DNA-copying phase compared with controls.

    Peptide
    Lanreotide
    Outcome
    DecreaseS-phase cell fraction
    Study

    humann: not reported in source

    Hep G2 cells
    Comparator
    controls
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A decrease of cells in the S-phase as compared to controls (p<0.03) followed by a significant, dose-dependent induction of apoptosis could be demonstrated in Hep G2 cells along with a dose-dependent influence of the peptide on cellular proliferation.
  11. 11LabIn vitro (cells)Efficacy outcome

    In Hep G2 cells, lanreotide significantly induced apoptosis in a dose-dependent manner.

    In plain wordsIn cells, lanreotide increased programmed cell death in a dose-dependent manner.

    Peptide
    Lanreotide
    Outcome
    IncreaseApoptosis
    Study

    humann: not reported in source

    Hep G2 cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A decrease of cells in the S-phase as compared to controls (p<0.03) followed by a significant, dose-dependent induction of apoptosis could be demonstrated in Hep G2 cells along with a dose-dependent influence of the peptide on cellular proliferation.
  12. 12LabIn vitro (cells)Efficacy outcome

    In Hep G2 cells, lanreotide influenced cellular proliferation in a dose-dependent manner; the result sentence does not state its direction.

    In plain wordsIn cells, lanreotide affected cell proliferation in a dose-dependent manner, but the result sentence does not state the direction.

    Peptide
    Lanreotide
    Outcome
    Direction not reportedCellular proliferation
    Study

    humann: not reported in source

    Hep G2 cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A decrease of cells in the S-phase as compared to controls (p<0.03) followed by a significant, dose-dependent induction of apoptosis could be demonstrated in Hep G2 cells along with a dose-dependent influence of the peptide on cellular proliferation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2/3NCT00495846

GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma

Federico II Universityn = 25Apr 2007 to Dec 2008

Advanced Hepatocellular Carcinoma

Trial pageClinicalTrials.govUpdated 17 Aug 2009

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.